gantenerumab   

GtoPdb Ligand ID: 6933

Synonyms: R-1450 | RG-1450 | Ro-4909832
Compound class: Antibody
Comment: Gantenerumab targets aggregated forms of human amyloid β (Aβ) proteins Aβ42 and Aβ40. This is in contrast to solanezumab which targets soluble Aβ.
Annotated peptide sequences for this antibody are available from its IMGT/mAb-DB record.
Protein sequence analysis reveals that gantenerumab is likely to be clone #7.9.H7 in patent US7794719 [1].
References
1. Bardroff M, Bohrmann B, Brockhaus M, Huber W, Kretzschmar T, Loetscher H, Löhning C, Nordstedt C, Rothe C. (2010)
variable regions peptides for immunizing against amyloid plaque formation; biodrug for dementia, Alzheimer's disease, neuropathy, Down's syndrome, Creutzfeld Jacob disease, Parkinson's disease, amyotropic lateral sclerosis; neuroprotectants; hemostatic agent.
Patent number: US7794719. Assignee: Hoffmann-La Roche Ag, Morphosys Ag. Priority date: 20/02/2002. Publication date: 14/09/2010.
2. Bohrmann B, Baumann K, Benz J, Gerber F, Huber W, Knoflach F, Messer J, Oroszlan K, Rauchenberger R, Richter WF et al.. (2012)
Gantenerumab: a novel human anti-Aβ antibody demonstrates sustained cerebral amyloid-β binding and elicits cell-mediated removal of human amyloid-β.
J. Alzheimers Dis., 28 (1): 49-69. [PMID:21955818]
3. Novakovic D, Feligioni M, Scaccianoce S, Caruso A, Piccinin S, Schepisi C, Errico F, Mercuri NB, Nicoletti F, Nisticò R. (2013)
Profile of gantenerumab and its potential in the treatment of Alzheimer's disease.
Drug Des Devel Ther, 7: 1359-64. [PMID:24255592]